O-GlcNAc Modification of PPARγ Reduces Its Transcriptional Activity
Overview
Affiliations
The peroxisome proliferator-activated receptor γ (PPARγ), a member of the nuclear receptor superfamily, is a key regulator of adipogenesis and is important for the homeostasis of the adipose tissue. The β-O-linked N-acetylglucosamine (O-GlcNAc) modification, a posttranslational modification on various nuclear and cytoplasmic proteins, is involved in the regulation of protein function. Here, we report that PPARγ is modified by O-GlcNAc in 3T3-L1 adipocytes. Mass spectrometric analysis and mutant studies revealed that the threonine 54 of the N-terminal AF-1 domain of PPARγ is the major O-GlcNAc site. Transcriptional activity of wild type PPARγ was decreased 30% by treatment with the specific O-GlcNAcase (OGA) inhibitor, but the T54A mutant of PPARγ did not respond to inhibitor treatment. In 3T3-L1 cells, an increase in O-GlcNAc modification by OGA inhibitor reduced PPARγ transcriptional activity and terminal adipocyte differentiation. Our results suggest that the O-GlcNAc state of PPARγ influences its transcriptional activity and is involved in adipocyte differentiation.
O-GlcNAcylation: Sagacious Orchestrator of Bone-, Joint-, and Spine-Related Diseases.
Wei G, Jia H, Zhang Z, Qin J, Ao J, Qian H J Proteome Res. 2025; 24(3):981-994.
PMID: 39921656 PMC: 11894655. DOI: 10.1021/acs.jproteome.4c00859.
Posta E, Fekete I, Varkonyi I, Zold E, Barta Z Cells. 2024; 13(20.
PMID: 39451206 PMC: 11505700. DOI: 10.3390/cells13201688.
Analysis of an adult diabetes mellitus caused by a rare mutation of the gene: A case report.
Li W, Xu L, Liu C, Dong B, Wang Y World J Clin Cases. 2024; 12(19):3942-3949.
PMID: 38994305 PMC: 11235441. DOI: 10.12998/wjcc.v12.i19.3942.
O-GlcNAcylation in ischemic diseases.
Shi R, He T, Lin M, Xu J, Gu J, Xu H Front Pharmacol. 2024; 15:1377235.
PMID: 38783961 PMC: 11113977. DOI: 10.3389/fphar.2024.1377235.
O-GlcNAcylation: cellular physiology and therapeutic target for human diseases.
Ye L, Ding W, Xiao D, Jia Y, Zhao Z, Ao X MedComm (2020). 2023; 4(6):e456.
PMID: 38116061 PMC: 10728774. DOI: 10.1002/mco2.456.